Grants for Small businesses - Federal

This funding opportunity supports small businesses in developing innovative technologies and services for population-wide genomic screening to improve primary care for common genetic conditions.

This grant provides funding for researchers to analyze and interpret data from various NASA planetary missions, encouraging innovative scientific investigations and collaborations in the field.

This funding opportunity supports the development and enhancement of animal models and related biological tools that are broadly applicable to various areas of biomedical research, aimed at improving our understanding of human diseases and advancing therapeutic interventions.

This funding opportunity announcement (FOA) encourages applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols.The NIH SIREN Network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for neurological emergencies.Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN. Applicants do not need to be part of the existing SIREN infrastructure to apply under this FOA.

The FY24 MRP Idea Award supports innovative, untested, exploratory, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods that address at least one of the FY24 MRP Focus Areas in Section II.A.1. Key aspects of the Idea Award: The intent of the Idea Award is to generate novel research avenues for investigation; therefore, novelty and innovation should be key aspects of the proposed research. Research supported by the Idea Award must introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other highly creative qualities. The proposed project must be exploratory, hypothesis-driven, or hypothesis-generating research and be based on a well-developed study design and plan of analysis. Principal Investigators (PIs) new to the melanoma field are encouraged to apply. The Idea Award is NOT intended to expand or extend previously published findings or continue a line of research already established and /or funded in the PIs laboratory. Incremental advances, the next logical step, or merely switching the object or method of inquiry from one cancer to melanoma is not considered innovative. The expected outcome of research supported by this award is the generation of robust preliminary data to be used as a foundation for future melanoma-focused research projects. Inclusion of preliminary data is discouraged. PIs proposing projects already supported by significant preliminary data and/or other funding sources should consider applying to other FY24 MRP funding opportunities for which the inclusion of preliminary data is more appropriate or required. Inclusion of preliminary data other than serendipitous findings is not consistent with the exploratory/innovative nature of this award. If preliminary data are included, they should be unanticipated outcomes or results from an unrelated project or study.

This funding opportunity is designed for researchers with existing NCI R01 grants to integrate innovative cancer research technologies into their projects, enhancing the study's impact and advancing the field of cancer research.

The FY24 LCRP Career Development Award supports early-career, independent investigators to conduct impactful research under the mentorship of an experienced lung cancer researcher as an opportunity to obtain the funding, mentoring, and experience necessary for productive, independent careers at the forefront of lung cancer research. Research applications only in the area of mesothelioma will not be accepted. This award is intended to support impactful research projects with an emphasis on discovery.Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated.Key elements of this award are as follows:Principal Investigator (PI): PIs must be research- or physician-scientists at an early stage of their independent research careers. PIs must be within 5 years of their first faculty appointment (or equivalent) and exhibit a strong desire to pursue a career in lung cancer research.Mentorship: The Mentor(s) must be an experienced lung cancer researcher(s) as demonstrated by a strong record of funding and publications in lung cancer research. In addition, the Mentor(s) must demonstrate a commitment to developing the PIs career in lung cancer research.Career Development: A Career Development Plan is required and should be prepared with appropriate guidance from the Mentor(s). A clearly articulated strategy for acquiring the necessary skills, competence, and expertise to have a career at the forefront of lung cancer research should be included. The plan should outline how the PI will gain experience in lung cancer research. Because career development is the focus of this award, the PI must commit a minimum of a 25% level of time and effort during the period of performance to conduct lung cancer research under this award.Impact: Research that has high potential impact may lead to major advancements and significantly accelerate progress toward eradicating deaths and suffering from lung cancer.Relevance to Military Health System (MHS) Beneficiaries: The application should clearly articulate how the proposed research is relevant to Service Members, Veterans, and their Families.The PI is required to attend a Department of Defense (DOD) one day in progress review meeting prior to the end of the second year of the award.

Some projects initiated with SBIR or STTR funding require considerable financing beyond the SBIR/STTR Phase II award to achieve commercialization. The development of medical biotechnology products is often impeded by a significant funding gap (known as the Valley of Death) between the end of the SBIR/STTR Phase II award and the commercialization stage. The goal of this FOA is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product/technology that requires Federal regulatory approval or to bring a complex research tool to market. This opportunity aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by promoting partnerships between NINDS SBIR or STTR awardees and third-party investors and/or strategic partners in the Phase IIB competing renewal. Applicants are strongly encouraged to secure independent third-party funding throughout the Phase IIB project period.

This grant provides funding for research aimed at identifying and overcoming financial and non-zoning obstacles to increasing the supply of diverse housing options, known as Missing Middle Housing, in communities across the United States.

The U.S. Department of State Bureau of Democracy, Human Rights, and Labor (DRL) announces an open competition for an evaluation project that contributes to building a portfolio of evidence regarding inclusive human rights in Ukraine. In support of this goal, DRL seeks to promote the use of sound data and generate findings on what works, for whom, and why in democracy and human rights programming abroad. Projects should support the following objective: the rights of marginalized, underserved, and at-risk individuals in Ukraine are recognized and respected within a democracy, rights, and good governance framework.

With this solicitation BJA seeks to assist state, local, and tribal jurisdictions in reducing crime and improving the functioning of the criminal justice system through more effective information sharing, multi-agency collaboration, and the implementation of data-driven, evidence-based strategies. This will be accomplished by providing support services to the Regional Information Sharing Systems (RISS) Centers and the RISS Technology Support Center (RTSC) under BJAs Justice Information Sharing Training and Technical Assistance (JISTTA) Program.

Scientific observations, experiments, and simulations are producing data at rates beyond our capacity to store, analyze, stream, and archive the data in raw form. Of necessity, many research groups have already begun reducing the size of their data sets via techniques such as compression, reduced order models, experiment-specific triggers, filtering, and feature extraction. Once reduced in size, transporting, storing, and analyzing the data is still a considerable challenge a reality that motivates SCs Integrated Research Infrastructure (IRI) program [1] and necessitates further innovation in data-reduction methods. These further efforts should continue to increase the level of mathematical rigor in scientific data reduction to ensure that scientifically-relevant constraints on quantities of interest are satisfied, that methods can be integrated into scientific workflows, and that methods are implemented in a manner that inspires trust that the desired information is preserved. Moreover, as the scientific community continues to drive innovation in artificial intelligence (AI), important opportunities to apply AI methods to the challenges of scientific data reduction and apply data-reduction techniques to enable scientific AI, continue to present themselves [2-4].The drivers for data reduction techniques constitute a broad and diverse set of scientific disciplines that cover every aspect of the DOE scientific mission. An incomplete list includes light sources, accelerators, radio astronomy, cosmology, fusion, climate, materials, combustion, the power grid, and genomics, all of which have either observatories, experimental facilities, or simulation needs that produce unwieldy amounts of raw data. ASCR is interested in algorithms, techniques, and workflows that can reduce the volume of such data, and that have the potential to be broadly applied to more than one application. Applicants who submit a pre-application that focuses on a single science application may be discouraged from submitting a full proposal.Accordingly, a virtual DOE workshop entitled Data Reduction for Science was held in January of 2021, resulting in a brochure [5] detailing four priority research directions (PRDs) identified during the workshop. These PRDs are (1) effective algorithms and tools that can be trusted by scientists for accuracy and efficiency, (2) progressive reduction algorithms that enable data to be prioritized for efficient streaming, (3) algorithms which can preserve information in features and quantities of interest with quantified uncertainty, and (4) mapping techniques to new architectures and use cases. For additional background, see [6-9].The principal focus of this FOA is to support applied mathematics and computer science approaches that address one or more of the identified PRDs. Research proposed may involve methods primarily applicable to high-performance computing, to scientific edge computing, or anywhere scientific data must be collected or processed. Significant innovations will be required in the development of effective paradigms and approaches for realizing the full potential of data reduction for science. Proposed research should not focus only on particular data sets from specific applications, but rather on creating the body of knowledge and understanding that will inform future scientific advances. Consequently, the funding from this FOA is not intended to incrementally extend current research in the area of the proposed project. Rather, the proposed projects must reflect viable strategies toward the potential solution of challenging problems in data reduction for science. It is expected that the proposed projects will significantly benefit from the exploration of innovative ideas or from the development of unconventional approaches. Proposed approaches may include innovative research with one or more key characteristics, such as compression, reduced order models, experiment-specific triggers, filtering, and feature extraction, and may focus on cross-cutting concepts such as artificial intelligence or trust. Preference may be given to pre-applications that include reduction estimates for at least two science applications.

This grant provides funding for innovative researchers to explore groundbreaking ideas and methods in glioblastoma research, particularly encouraging early-career scientists and collaborations with experienced experts.

This funding opportunity supports innovative research projects focused on understanding and advancing treatments for nonmalignant blood disorders, encouraging collaboration and involvement from new researchers in the field.

DOE is seeking input from universities, national laboratories, industry, and international entities regarding future work scopes for its major NE-funded research programs. This input includes research ideas, information, comments, feedback, and recommendations. All responses should be submitted via NEUP.gov as per the attached instructions. Eligible applicants include nonprofits with or without 501(c)(3) status, private and public institutions of higher education, for-profit organizations other than small businesses, and small businesses. The grant aims to gather comprehensive input to guide the Office of Nuclear Energy's competitive research and development efforts.

The OCRP Pilot Award supports the exploration of innovative concepts or theories in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward. The proposed research must demonstrate a clear focus on ovarian cancer (e.g., using tissues, cell lines, datasets, or appropriate animal models), and serve as a catalyst to expand or modify current thinking about and/or approaches in ovarian cancer. If cell lines or animals are to be used, a clear justification should be provided for the choice of proposed cell line(s) or animal model(s).

To obtain a copy of the Funding Opportunity Announcement (FOA) please go to the ARPA-E website at https://arpa-e-foa.energy.gov. To apply to this FOA, Applicants must register with and submit application materials through ARPA-E eXCHANGE (https://arpa-e-foa.energy.gov/Registration.aspx). For detailed guidance on using ARPA-E eXCHANGE, please refer to the ARPA-E eXCHANGE User Guide (https://arpa-e-foa.energy.gov/Manuals.aspx). ARPA-E will not review or consider concept papers submitted through other means. For problems with ARPA-E eXCHANGE, email [email protected] (with FOA name and number in the subject line). Questions about this FOA? Check the Frequently Asked Questions available at http://arpa-e.energy.gov/faq. For questions that have not already been answered, email [email protected]. Agency Overview: The Advanced Research Projects Agency Energy (ARPA-E), an organization within the Department of Energy (DOE), is chartered by Congress in the America COMPETES Act of 2007 (P.L. 110-69), as amended by the America COMPETES Reauthorization Act of 2010 (P.L. 111-358), as further amended by the Energy Act of 2020 (P.L. 116-260): (A) to enhance the economic and energy security of the United States through the development of energy technologies that (i) reduce imports of energy from foreign sources; (ii) reduce energy-related emissions, including greenhouse gases; (iii) improve the energy efficiency of all economic sectors; (iv) provide transformative solutions to improve the management, clean-up, and disposal of radioactive waste and spent nuclear fuel; and (v) improve the resilience, reliability, and security of infrastructure to produce, deliver, and store energy; and (B) to ensure that the United States maintains a technological lead in developing and deploying advanced energy technologies. ARPA-E issues this Funding Opportunity Announcement (FOA) under its authorizing statute codified at 42 U.S.C. 16538. The FOA and any cooperative agreements or grants made under this FOA are subject to 2 C.F.R. Part 200 as supplemented by 2 C.F.R. Part 910. ARPA-E funds research on, and the development of, transformative science and technology solutions to address the energy and environmental missions of the Department. The agency focuses on technologies that can be meaningfully advanced with a modest investment over a defined period of time in order to catalyze the translation from scientific discovery to early-stage technology. For the latest news and information about ARPA-E, its programs and the research projects currently supported, see: http://arpa-e.energy.gov/. ARPA-E funds transformational research. Existing energy technologies generally progress on established learning curves where refinements to a technology and the economies of scale that accrue as manufacturing and distribution develop drive improvements to the cost/performance metric in a gradual fashion. This continual improvement of a technology is important to its increased commercial deployment and is appropriately the focus of the private sector or the applied technology offices within DOE. In contrast, ARPA-E supports transformative research that has the potential to create fundamentally new learning curves. ARPA-E technology projects typically start with cost/performance estimates well above the level of an incumbent technology. Given the high risk inherent in these projects, many will fail to progress, but some may succeed in generating a new learning curve with a projected cost/performance metric that is significantly better than that of the incumbent technology. ARPA-E funds technology with the potential to be disruptive in the marketplace. The mere creation of a new learning curve does not ensure market penetration. Rather, the ultimate value of a technology is determined by the marketplace, and impactful technologies ultimately become disruptive that is, they are widely adopted and displace existing technologies from the marketplace or create entirely new markets. ARPA-E understands that definitive proof of market disruption takes time, particularly for energy technologies. Therefore, ARPA-E funds the development of technologies that, if technically successful, have clear disruptive potential, e.g., by demonstrating capability for manufacturing at competitive cost and deployment at scale. ARPA-E funds applied research and development. The Office of Management and Budget defines applied research as an original investigation undertaken in order to acquire new knowledgedirected primarily towards a specific practical aim or objective and defines experimental development as creative and systematic work, drawing on knowledge gained from research and practical experience, which is directed at producing new products or processes or improving existing products or processes. Applicants interested in receiving financial assistance for basic research (defined by the Office of Management and Budget as experimental or theoretical work undertaken primarily to acquire new knowledge of the underlying foundations of phenomena and observable facts) should contact the DOEs Office of Science (http://science.energy.gov/). Office of Science national scientific user facilities (http://science.energy.gov/user-facilities/) are open to all researchers, including ARPA-E Applicants and awardees. These facilities provide advanced tools of modern science including accelerators, colliders, supercomputers, light sources and neutron sources, as well as facilities for studying the nanoworld, the environment, and the atmosphere. Projects focused on early-stage R for the improvement of technology along defined roadmaps may be more appropriate for support through the DOE applied energy offices including: the Office of Energy Efficiency and Renewable Energy (http://www.eere.energy.gov/), the Office of Fossil Energy and Carbon Management (https://www.energy.gov/fecm/office-fossil-energy-and-carbon-management), the Office of Nuclear Energy (http://www.energy.gov/ne/office-nuclear-energy), and the Office of Electricity (https://www.energy.gov/oe/office-electricity). Program Overview: The energy transition towards net-zero by 2050 demands an unprecedented level of innovation that must be completed in the span of a generation. Global primary energy usage has increased continuously for the past century. This increase is expected to continue with improved standards of living and the rapid expansion of new technologies with high levels of energy-intensive computation, such as artificial intelligence. Present grid capacity is constrained and cannot accommodate these increasing primary energy needs to reliably deliver power on demand. Meanwhile, all paths through the energy transition require concurrent efforts to decouple the production of essential carbon-based materials from harmful greenhouse gas (GHG) emissions. Since the Agencys inception, the ARPA-E OPEN program has served as an opportunity to advance transformative energy breakthroughs in critical areas that fall outside the scope of its technology-focused programs. Vision OPEN challenges the research community to develop groundbreaking technologies to enable a future energy landscape that is dramatically different. The Vision includes three goals that are critical to achieve a sustainable energy and carbon transition with: 1) GHG-free abundant primary energy; 2) An intermodal energy superhighway that transports diversified forms of primary energy; and 3) A carbon transition that sustainably meets demand for polymers and other materials. To view the FOA in its entirety, please visit https://arpa-e-foa.energy.gov.

The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.

The CTRA supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis, or treatment of TSC. Projects supported by this award mechanism may include, but are not limited to: Studies moving from preclinical to clinical research and/or the reverse; or analyzing human anatomical substances and/or data associated with completed clinical trials to understand the mechanism of action, or to improve diagnosis, prognosis, or treatment. Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of pharmacokinetics/pharmacodynamics. Pilot clinical trials, where limited clinical testing (e.g., small sample size) of a novel intervention to produce information on diagnostic or therapeutic effectiveness, safety, tolerability, or mechanisms of action. These studies should be aimed at obtaining preliminary data leading to the development of interventions with the potential to improve TSC outcomes. New Studies improving clinical care of TSC encompassing the analysis of existing real-world clinical practice data to develop/improve guidelines for better outcomes in defined areas relevant to the FY24 TSCRP focus areas, include but are not limited to epilepsy surgery, tumor resection, reproductive health, perinatal surveillance and care, etc.Preclinical studies may be appropriate but must include a clinical component. Projects that are strictly animal research will not be considered for CTRA funding and should consider other FY24 TSCRP funding opportunities.

This grant provides funding for innovative research projects focused on understanding and treating rare cancers, targeting researchers and institutions dedicated to advancing medical knowledge in this area.